Crestwood Advisors Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.9M | Buy |
122,966
+2,869
| +2% | +$617K | 0.46% | 54 |
|
|
2026
Q1 | $26.1M | Buy |
120,097
+880
| +0.7% | +$195K | 0.44% | 59 |
|
|
2025
Q4 | $27.2M | Sell |
119,217
-797
| -0.7% | -$182K | 0.45% | 62 |
|
|
2025
Q3 | $27.8M | Buy |
120,014
+1,925
| +2% | +$392K | 0.47% | 65 |
|
|
2025
Q2 | $21.9M | Sell |
118,089
-1,004
| -0.8% | -$187K | 0.39% | 70 |
|
|
2025
Q1 | $25M | Buy |
119,093
+6,072
| +5% | +$1.18M | 0.47% | 63 |
|
|
2024
Q4 | $20.1M | Buy |
113,021
+2,305
| +2% | +$424K | 0.38% | 69 |
|
|
2024
Q3 | $21.9M | Buy |
110,716
+1,652
| +2% | +$308K | 0.42% | 70 |
|
|
2024
Q2 | $18.7M | Sell |
109,064
-225
| -0.2% | -$37.3K | 0.39% | 71 |
|
|
2024
Q1 | $19.9M | Sell |
109,289
-937
| -0.9% | -$161K | 0.43% | 67 |
|
|
2023
Q4 | $17.1M | Sell |
110,226
-78
| -0.1% | -$11.4K | 0.4% | 67 |
|
|
2023
Q3 | $16.4M | Buy |
110,304
+97,799
| +782% | +$14.4M | 0.43% | 65 |
|
|
2023
Q2 | $1.68M | Buy |
12,505
+982
| +9% | +$144K | 0.05% | 116 |
|
|
2023
Q1 | $1.84M | Sell |
11,523
-1,592
| -12% | -$243K | 0.06% | 111 |
|
|
2022
Q4 | $2.12M | Sell |
13,115
-1,183
| -8% | -$181K | 0.07% | 110 |
|
|
2022
Q3 | $1.92M | Buy |
14,298
+126
| +0.9% | +$18.1K | 0.07% | 116 |
|
|
2022
Q2 | $2.17M | Sell |
14,172
-1,613
| -10% | -$246K | 0.07% | 115 |
|
|
2022
Q1 | $2.56M | Sell |
15,785
-1,060
| -6% | -$154K | 0.07% | 116 |
|
|
2021
Q4 | $2.28M | Buy |
16,845
+4,912
| +41% | +$580K | 0.06% | 117 |
|
|
2021
Q3 | $1.29M | Buy |
11,933
+515
| +5% | +$58.8K | 0.04% | 139 |
|
|
2021
Q2 | $1.29M | Buy |
11,418
+430
| +4% | +$48.4K | 0.04% | 141 |
|
|
2021
Q1 | $1.19M | Sell |
10,988
-491
| -4% | -$52.5K | 0.04% | 140 |
|
|
2020
Q4 | $1.23M | Buy |
11,479
+898
| +8% | +$86.3K | 0.04% | 135 |
|
|
2020
Q3 | $927K | Buy |
10,581
+1,338
| +14% | +$126K | 0.03% | 130 |
|
|
2020
Q2 | $907K | Buy |
9,243
+611
| +7% | +$53.8K | 0.04% | 125 |
|
|
2020
Q1 | $658K | Sell |
8,632
-90
| -1% | -$7.67K | 0.03% | 135 |
|
|
2019
Q4 | $772K | Buy |
8,722
+200
| +2% | +$16.6K | 0.03% | 148 |
|
|
2019
Q3 | $645K | Buy |
8,522
+93
| +1% | +$6.38K | 0.03% | 153 |
|
|
2019
Q2 | $613K | Buy |
+8,429
| New | +$663K | 0.03% | 148 |
|
|
2018
Q1 | – | Sell |
-2,541
| Closed | -$246K | – | 180 |
|
|
2017
Q4 | $246K | Buy |
+2,541
| New | +$239K | 0.02% | 158 |
|
|
2017
Q2 | – | Sell |
-1,408
| Closed | -$94K | – | 162 |
|
|
2017
Q1 | $94K | Buy |
+1,408
| New | +$88.5K | 0.01% | 201 |
|
|
2016
Q3 | – | Sell |
-4,632
| Closed | -$287K | – | 130 |
|
|
2016
Q2 | $287K | Buy |
4,632
+230
| +5% | +$14K | 0.04% | 107 |
|
|
2016
Q1 | $251K | Sell |
4,402
-195
| -4% | -$10.9K | 0.03% | 119 |
|
|
2015
Q4 | $272K | Buy |
+4,597
| New | +$265K | 0.03% | 121 |
|
|
2015
Q1 | – | Sell |
-3,074
| Closed | -$201K | – | 146 |
|
|
2014
Q4 | $201K | Buy |
+3,074
| New | +$194K | 0.03% | 139 |
|
Other funds holding ABBV
Crestwood Advisors Group's ABBV Position: Q2 2026 in Review
Crestwood Advisors Group increased its AbbVie (ABBV) stake by 2.4% in Q2 2026, buying an estimated $617K and bringing the position to 122,966 shares worth $30.9M. The position accounts for 0.46% of the portfolio, ranked #54.
Crestwood Advisors Group first reported a position in ABBV in Q4 2014 and has held it in 35 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Crestwood Advisors Group held 122,966 shares of AbbVie worth $30.9M as of Q2 2026.
- Crestwood Advisors Group bought 2,869 AbbVie shares in Q2 2026, an estimated $617K.
- AbbVie made up 0.46% of Crestwood Advisors Group's portfolio in Q2 2026, its #54 holding.
- Crestwood Advisors Group first reported a position in AbbVie in Q4 2014 and has held it in 35 quarters since.
- 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.